- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Selvita pharma's backlog for 2024 amounts to PLN 197 mln | 2 | PAP | ||
| 18.03. | Selvita Adds Antibody Discovery and Development Capabilities | 1 | Contract Pharma | ||
| 18.03. | Selvita Ventures Into Biologic Drug Discovery And Development | - | RTTNews | ||
| 31.05.23 | Selvita S.A.: Selvita Q1 2023 financial results exceed initial estimates, the Company is preparing for further dynamic growth | 243 | PR Newswire | KRAKÓW, Poland, May 31, 2023 /PRNewswire/ -- Selvita S.A. [WSE: SLV], one of the largest contract research organization companies in Europe, has published a financial report for Q1 2023*. The Group... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,137 | -3,18 % | Sondermeldung: Gar mehrere hundert Prozent bis zur Bescherung? Wo die Community jetzt auf eine Jahresendrallye spekuliert… | ||
| PALATIN TECHNOLOGIES | 1,612 | 0,00 % | Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive | WASHINGTON (dpa-AFX) - Biopharmaceutical company Palatin Technologies, Inc. (PTN) Monday said it presented positive topline results from the Phase 3 MELODY-1 study of its drug candidate PL9643... ► Artikel lesen | |
| AETERNA ZENTARIS | 1,800 | -2,70 % | Aeterna Zentaris Inc: Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris | TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) ("Ceapro") are pleased to announce... ► Artikel lesen | |
| AMYRIS | 0,039 | 0,00 % | AMYRIS, INC. - 8-K, Current Report | ||
| HALOZYME THERAPEUTICS | 37,060 | +1,45 % | Halozyme Therapeutics, Inc.: Halozyme Reports Fourth Quarter And Full Year 2023 Financial And Operating Results | Reiterating 2024 Financial Guidance: Total Revenue of $915 -985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535 -585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted... ► Artikel lesen | |
| GLOW LIFETECH | 0,028 | 0,00 % | Glow LifeTech Corp.: Glow Announces Late Filing of Financial Statements | Toronto, Ontario--(Newsfile Corp. - April 18, 2024) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) ("Glow" or the "Company") announces that the Company is currently seeking a new auditor to perform... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,665 | +0,69 % | AbCellera Reports Full Year 2023 Business Results | VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported in U.S.... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 257,60 | -0,92 % | OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay | - Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option... ► Artikel lesen | |
| AVID BIOSERVICES | 6,200 | -3,12 % | Avid Bioservices, Inc: Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 | -- Recorded Third Quarter Revenue of $33.8 Million -- -- Signed $41 Million in Net New Business Resulting in Record High Backlog of $206 Million -- -- Celebrated Completion of Recent Expansion Program... ► Artikel lesen | |
| BIOLINERX | 0,605 | +5,22 % | BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting | TEL AVIV, Israel, April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases... ► Artikel lesen | |
| AADI BIOSCIENCE | 1,720 | +2,99 % | Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) | Subgroup experienced efficacy and safety consistent with overall study population
Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,340 | 0,00 % | Minerva Neurosciences, Inc. - 10-K/A, Annual Report | ||
| OVID THERAPEUTICS | 3,000 | +1,35 % | Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review | RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders... ► Artikel lesen | |
| COCRYSTAL | 1,420 | -1,39 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs | FDA feedback following the Company's submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum... ► Artikel lesen | |
| GEOVAX LABS | 1,743 | -100,00 % | GeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine | Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing... ► Artikel lesen |
Das Unternehmen SELVITA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 15,520 Euro und damit -1,65 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
